Last reviewed · How we verify

NCT05777837

Laparoscopic Versus Combined Laparoscopic and Hysteroscopic Repair of CS Niche

Status unknown NA Last updated 21 March 2023
What this trial tests

NA trial testing laparoscopic repair of cesarean scar niche in Cesarean Scar Niche in 30 participants. Status unknown.

Timeline
1 April 2023
Primary endpoint
1 April 2024
1 May 2024

Quick facts

Lead sponsorZagazig University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date1 April 2023
Primary completion1 April 2024
Estimated completion1 May 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Zagazig University

Who can join

Adults 18 to 40, female only, with Cesarean Scar Niche. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Uterine niche is a frequent condition in patients with a history of cesarean section. Many treatment methods have been described for repair of niche with varying effectivities. In conventional Laparoscopic approach, not all bleeding points and fibrotic area are resected, while conventional hysteroscopic one result in more wide defect with high risk of recurrence and cannot be used in large niche with low RMT. In this new Double approach (hysteroscopy and laparoscopy) technique, the benefit of both laparoscopy and hysteroscopy will be attained.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cesarean Scar Niche

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05777837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing